Experience:
0-1 years of experience
Concerned about your lack of experience? Learn More...
Employment Type:
Intern/Co-op
Posted:
2/20/2019
Job Category:
Information Services
MBA Intern: Alliance Management and Integration
(This job is no longer available)
Biogen Idec | Cambridge, MA
loading
loading
School
Major
Grad Date
 
 

Not sure what types of jobs you are interested in?


Explore Jobs
Based on Your Education

Follow This Company
Share

Job Description

Job Description

Biogen is currently seeking MBA summer interns to support our Alliance Management and Integration team, within Corporate Development. This team is responsible for managing partnerships and integrating companies and assets acquired by Biogen.

Projects for the MBA Interns will include:

* Developing an Alliance Health and Alliance Value dashboard, working extensively with Biogen's VP of Alliance Management and cross functional partners
* Creating a cross functional integration tool kit with functional stakeholders for complete and arms-length integration scenarios

The role(s) will be based in Cambridge, MA.

Qualifications

* Enthusiastic to work in cross functional environment to build systems and tools
* System level thinking to synthesize implementable concepts, content and tools with cross-functional partners
* Excellent working knowledge of data metrics and visualization tools
* Excellent project and time management skills
* High competency in using project management, presentation tools
* Excellent team work, collaboration and communication skills
* Previous experience in pharma or biotech is preferred

Education

* Enrolled in an accredited MBA Program with graduation planned for 2020.
* Concentration: Healthcare
* Bachelors required; in related field preferred business, science or technology

About Biogen Idec

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company's products address diseases such as multiple sclerosis, lymphoma and rheumatoid arthritis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is used in the treatment of relapsed or refractory low-grade or follicular, CD20-positive, and B-cell, non-Hodgkin's lymphomas (B-cell NHLs). TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. It also has product candidates, such as BG-12 (acquired with the purchase of Fumapharm), ANTI-CD80 antibody/(galiximab), ANTI-CD23 antibody/(lumiliximab), Ocrelizumab/(Humanized ANTI-CD20 Antibody) and Lixivaptan.In January 2007, the Company completed the acquisition of Syntonix Pharmaceuticals, Inc. (Source: 10-K)